Fosun Pharmaceutical (02196) announced interim results after deducting non-net profit of about 1,144 billion yuan, a year-on-year increase of 19.09%

According to the Zhitong Finance App, Fosun Pharmaceutical (02196) announced its 2026 interim results, with operating income of about 20.442 billion yuan, up 4.75% year on year; net profit attributable to shareholders of listed companies was about 1,721 billion yuan, up 1.15% year on year; after deducting non-net profit of about 1,144 billion yuan, up 19.09% year on year; basic earnings per share were 0.65 yuan. Net cash flow from operating activities was approximately $2,424 million, an increase of 13.59% over the previous year.

According to the announcement, revenue growth was mainly due to the steady growth of innovative pharmaceuticals and overseas business; excluding the impact of exchange rate fluctuations, the year-on-year increase was 7.17% based on a constant exchange rate. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss increased 19.09% year-on-year during the reporting period, mainly due to steady growth in operating income; excluding the impact of exchange rate fluctuations, the year-on-year increase was 21.97% based on a constant exchange rate.